The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Recent Progress in the Management of Gouty Arthritis and Hyperuricemia

통풍의 치료

  • Park, Won (Division of Rheumatology, Department of Internal Medicine, Inha University School of Medicine, Center for Rheumatism, Inha University Hospital)
  • 박원 (인하대학교 의과대학 내과학교실 류마티스내과, 인하대병원 류마티즘센터)
  • Published : 2011.03.01
⟨ Previous Next ⟩

Abstract

There is an increasing incidence of gout and hyperuricemia worldwide. It is because the population is getting older, their life style is sedentary, and they take protein-enriched food. Gout is one of the most common but best controllable chronic diseases of adult. There have been recent advances in the understanding of underlying mechanisms and treatment of gout and hyperuricemia. This article is aimed to provide the practical review of the currently recommended practice of care and also to introduce some recently approved drugs. The management concept of hyperuricemia is changing because not only the gout but also the hyperuricemia appear to be independent risk factors for hypertension, renal disease and cardiovascular disease. Gout causes a significant individual and social burden and loss of working force. Still hyperuricemia in the gout patient is often under-treated by the patients themselves and by the physicians also. Once the acute gout attack is controlled, patients should be followed with goal-oriented treatment of hyperuricemia and other risk factors. Allopurinol has remained as a first-line treatment for chronic hyperuricemia, but uricosuric agents may also be considered in some patients. These drugs have provided good control of the disease in most gout patients until now but the elderly patients with gout often carry co-medications, contra-indication to these drugs, and risk of adverse drug reaction. Febuxostat is a nonpurine xanthine-oxidase inhibitor. It is a new agent approved by the US FDA and Korean FDA for the treatment of hyperuricemia in patients with gout which may be used when allopurinol is not tolerated or contraindicated. Pegloticase is the PEGylated urate oxidase which is very potent and so recently approved by the US FDA for the gout refractory to conventional treatment.

Keywords

References

  1. 정영옥. 통풍의 최신지견. 대한내과학회지 2009;76:538-543.
  2. Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract 2010;64:371-377. https://doi.org/10.1111/j.1742-1241.2009.02188.x
  3. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008;58:26-35. https://doi.org/10.1002/art.23176
  4. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324. https://doi.org/10.1136/ard.2006.055269
  5. Yamanaka H. A New Wave in Treating Gout and Hyperuricemia by a Novel Xanthine Oxidase Inhibitor Febuxostat. 대한류마티스학회지 2010;17(Suppl 2):S45-S46.
  6. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-38. https://doi.org/10.1038/nrrheum.2009.236
  7. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-2286.
  8. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
  9. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377:165-177. https://doi.org/10.1016/S0140-6736(10)60665-4
  10. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241. https://doi.org/10.1038/nature04516
  11. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28. https://doi.org/10.1186/ar2143
  12. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68: 1613-1617. https://doi.org/10.1136/ard.2009.108936
  13. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-3076. https://doi.org/10.1002/art.27600
  14. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the third National Health and Nutrition Examination Survey. Arthritis Rheum 2008;59:109-116. https://doi.org/10.1002/art.23245
  15. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-289. https://doi.org/10.1002/art.20761
  16. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007;57:816-821. https://doi.org/10.1002/art.22762
  17. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol 2008;35:1853-1858.
  18. Chang WC. Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men. Aging Male 2010. (doi:10.3109/13685538.2010.512372)
  19. Reinders MK, Jansen TL. Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 2010;5:7-18.
  20. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51: 321-325. https://doi.org/10.1002/art.20405
  21. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? DrugSaf 2008;31:643-665.
  22. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994;9:548-551.
  23. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002;17:625-626. https://doi.org/10.1046/j.1440-1746.2002.02692.x
  24. Taniguchi A, Kamatani N. Control of renal uric acid excretion and gout. Curr Opin Rheumatol 2008;20:192-197. https://doi.org/10.1097/BOR.0b013e3282f33f87
  25. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007;20:391-395. https://doi.org/10.1111/j.1525-139X.2007.00270.x
  26. Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med 1998;52:107-110. https://doi.org/10.1016/S0300-2977(97)00088-0
  27. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
  28. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983. https://doi.org/10.1136/ard.60.10.981
  29. Hung SI, Chung WH, Liou LB, et al. $HLA-B^{\ast}5801$ allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139. https://doi.org/10.1073/pnas.0409500102
  30. Becker MA, Schumacher HR, Espinoza LR, et al. The uratelowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63. https://doi.org/10.1186/ar2978
  31. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-1548. https://doi.org/10.1002/art.24209
  32. Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007;34:2093-2098.